Q-omics provides the consensus-scored CTSLP6 profile across patient tissues and cancer cell-line models. CTSLP6 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTSLP6 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, CTSLP6 RNA expression shows 5,777 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where CTSLP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTSLP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTSLP6 survival associations across molecular data types. CTSLP6 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTSLP6 RNA expression–survival associations across cancer types. High CTSLP6 expression shows unfavorable associations in KIRC, STAD, UVM, UCEC, ACC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTSLP6 RNA expression.
This table summarizes CTSLP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CTSLP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTSLP6 shows lower tumor expression in KIRC, KICH, UCEC, KIRP and THCA and higher tumor expression in ESCA. The KIRC box plot shows higher CTSLP6 RNA expression in normal versus tumor tissue (log2 FC = −0.123, t-test p < 0.001).
This table shows molecular features associated with CTSLP6 in patient tissues and cancer cell lines. In patient samples, CTSLP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
